https://news.medxy.ai/zh/77192-2/Medxy AIzh2026-09-21T16:30:11-07:00 https://news.medxy.ai/ja/copd-ct-classification/Medxy AIja2026-09-21T16:29:51-07:00定量的CTで見えるCOPDの新分類：粘液栓・肺気腫の混合表現型が増悪リスクを予測する https://news.medxy.ai/vi/mucus-airway-phenotype/Medxy AIvi2026-09-21T16:29:25-07:00Kiểu hình hóa phối hợp nút nhầy–khí phế thũng trên CT định lượng dự báo nguy cơ đợt cấp trong COPD: Tích hợp dấu ấn sinh học hình ảnh cho y học chính xác https://news.medxy.ai/zh/us-bronchiectasis-trends/Medxy AIzh2026-09-21T16:07:07-07:00美国初级保健中非囊性纤维化支气管扩张症负担持续上升：2015—2025年患病趋势与人口学特征分析 https://news.medxy.ai/ja/77186-2/Medxy AIja2026-09-21T16:06:51-07:00 https://news.medxy.ai/vi/bronchiectasis-us-increase/Medxy AIvi2026-09-21T16:06:33-07:00Giãn phế quản không do xơ nang tại chăm sóc ban đầu ở Hoa Kỳ gia tăng rõ rệt: Xu hướng hiện mắc trong một thập kỷ và đặc điểm nhân khẩu học (2015–2025) https://news.medxy.ai/zh/airway-assessment-pediatric-arrest/Medxy AIzh2026-09-21T16:00:34-07:00通过波形二氧化碳描记法评估气道通畅性，优化儿科心搏骤停结局 https://news.medxy.ai/ja/77181-2/Medxy AIja2026-09-21T16:00:17-07:00 https://news.medxy.ai/vi/pediatric-cardiac-arrest/Medxy AIvi2026-09-21T15:59:56-07:00Tối ưu hóa kết cục ngừng tim ở trẻ em thông qua đánh giá tình trạng thông thoáng đường thở bằng capnography https://news.medxy.ai/zh/retinal-vessel-glaucoma/Medxy AIzh2026-09-21T15:59:03-07:00自动眼底摄影揭示：视网膜血管特征可预测原发性开角型青光眼的视野进展 https://news.medxy.ai/ja/77176-2/Medxy AIja2026-09-21T15:58:45-07:00 https://news.medxy.ai/vi/retinal-vessel-quantification/Medxy AIvi2026-09-21T15:58:26-07:00Định lượng mạch máu võng mạc có dự báo tiến triển thị trường ở tăng nhãn áp góc mở nguyên phát? Phân tích từ ảnh đáy mắt tự động https://news.medxy.ai/zh/stevens-johnson-vision-loss/Medxy AIzh2026-09-21T15:57:32-07:00慢性 Stevens-Johnson 综合征视力丧失的预测因素：来自全国多中心队列研究的启示 https://news.medxy.ai/ja/stevens-johnson-vision/Medxy AIja2026-09-21T15:57:14-07:00慢性Stevens-Johnson症候群における視力低下の予測因子：全国多施設コホート研究からの知見 https://news.medxy.ai/vi/vision-loss-prediction-stevens-johnson/Medxy AIvi2026-09-21T15:56:57-07:00Yếu tố dự báo mất thị lực trong Stevens-Johnson syndrome mạn tính: Góc nhìn từ một nghiên cứu đoàn hệ đa trung tâm trên phạm vi toàn quốc https://news.medxy.ai/zh/laryngoscopy-smart-assessment/Medxy AIzh2026-09-21T15:56:02-07:00喉镜检查迈向实时智能评估：基于声带运动学的喉功能行为分类 https://news.medxy.ai/ja/larynx-function-analysis/Medxy AIja2026-09-21T15:55:48-07:00声帯運動学で切り拓く喉頭検査の新展開：機能的喉頭行動をリアルタイム分類 https://news.medxy.ai/vi/real-time-vocal-fold-analysis/Medxy AIvi2026-09-21T15:55:30-07:00Nâng tầm thăm khám thanh quản: Phân loại hành vi chức năng theo thời gian thực dựa trên động học dây thanh âm https://news.medxy.ai/zh/dysphagia-surgery-outcomes/Medxy AIzh2026-09-21T15:54:40-07:00衰弱是否会影响环咽肌功能障碍手术结局？——优化患者筛选与预期管理 https://news.medxy.ai/ja/pharyngeal-muscle-frailty/Medxy AIja2026-09-21T15:54:21-07:00輪状咽頭筋機能障害における手術転帰予測因子としてのフレイル：患者選択と期待値設定の最適化 https://news.medxy.ai/vi/surgery-outcomes-prediction/Medxy AIvi2026-09-21T15:54:01-07:00Suy yếu có dự báo kết quả phẫu thuật trong rối loạn chức năng cơ nhẫn hầu không? Tối ưu lựa chọn bệnh nhân và kỳ vọng điều trị https://news.medxy.ai/zh/chronic-rhinosinusitis-pathology/Medxy AIzh2026-09-21T15:53:02-07:00鼻内物质使用相关慢性鼻-鼻窦炎的组织病理学新认识：对临床管理的启示 https://news.medxy.ai/ja/77156-2/Medxy AIja2026-09-21T15:52:44-07:00 https://news.medxy.ai/vi/chronic-rhinosinusitis-findings/Medxy AIvi2026-09-21T15:52:24-07:00Những phát hiện mô bệnh học trong viêm mũi xoang mạn tính liên quan đến sử dụng chất qua đường mũi: hàm ý cho quản lý lâm sàng https://news.medxy.ai/zh/environmental-impact-surgery/Medxy AIzh2026-09-21T15:51:28-07:00环境负担如何影响手术结局：揭开隐匿的健康差异 https://news.medxy.ai/ja/environmental-impact-surgery/Medxy AIja2026-09-21T15:51:14-07:00環境負荷は外科成績にどう影響するのか――見えにくい格差を読み解く https://news.medxy.ai/vi/environmental-burden-surgery-impact/Medxy AIvi2026-09-21T15:50:55-07:00Gánh nặng môi trường và tác động lên kết cục phẫu thuật: hé lộ những chênh lệch ẩn giấu https://news.medxy.ai/zh/automated-gastrectomy-quality/Medxy AIzh2026-09-21T15:49:57-07:00远端胃切除术质量评估再升级：基于计算机视觉的质量关键视野自动化判读 https://news.medxy.ai/ja/gastrectomy-quality-evaluation/Medxy AIja2026-09-21T15:49:39-07:00遠位胃切除術の手術品質評価を前進させる：Computer Vision による Critical View of Quality の自動解析 https://news.medxy.ai/vi/surgical-quality-assessment/Medxy AIvi2026-09-21T15:49:21-07:00Nâng tầm đánh giá chất lượng phẫu thuật trong cắt dạ dày xa: Đánh giá tự động Critical View of Quality bằng computer vision https://news.medxy.ai/zh/neurotensin-receptor1/Medxy AIzh2026-09-21T15:48:26-07:00神经降压素受体1：驱动结直肠癌免疫排斥与不良预后的关键因素 https://news.medxy.ai/ja/neurotensin-receptor1-colon-cancer/Medxy AIja2026-09-21T15:48:09-07:00ニューロテンシン受容体1が切り拓く大腸がんの免疫排除機構と予後不良の鍵 https://news.medxy.ai/vi/neurotensin-receptor-1/Medxy AIvi2026-09-21T15:47:51-07:00Thụ thể Neurotensin 1: Động lực then chốt của hiện tượng loại trừ miễn dịch và tiên lượng xấu trong ung thư đại trực tràng https://news.medxy.ai/zh/early-treatment-severe-preeclampsia/Medxy AIzh2026-09-21T15:46:50-07:00早发型重度子痫前期中降压治疗升级：期待治疗期间母体风险的动态标志 https://news.medxy.ai/ja/early-severe-preeclampsia/Medxy AIja2026-09-21T15:46:33-07:00早発性重症子癇前症における降圧治療増強：待機的管理中の母体リスクを示す動的マーカー https://news.medxy.ai/vi/early-pre-eclampsia-treatment/Medxy AIvi2026-09-21T15:46:13-07:00Tăng cường điều trị hạ huyết áp trong tiền sản giật khởi phát sớm có đặc điểm nặng: chỉ dấu động về nguy cơ mẹ trong xử trí theo dõi chờ đợi https://news.medxy.ai/zh/ontario-hysterectomy-trends/Medxy AIzh2026-09-21T15:44:39-07:00安大略省门诊子宫切除术的上升趋势及临床结局：基于人群的分析 https://news.medxy.ai/ja/77114-2/Medxy AIja2026-09-21T15:44:23-07:00 https://news.medxy.ai/vi/outpatient-hysterectomy-ontario/Medxy AIvi2026-09-21T15:44:05-07:00Cắt tử cung ngoại trú tại Ontario tăng nhanh cùng kết cục lâm sàng khả quan: phân tích dựa trên quần thể https://news.medxy.ai/zh/microbiome-necrotizing-enterocolitis/Medxy AIzh2026-09-21T15:43:10-07:00坏死性小肠结肠炎中的微生物差异机制与预测特征：肠道噬菌体与细菌耐药组的作用 https://news.medxy.ai/ja/necrotizing-enterocolitis-mechanisms/Medxy AIja2026-09-21T15:42:49-07:00壊死性腸炎における微生物機序の分岐と予測シグネチャー：腸内ファージと細菌レジストームの役割 https://news.medxy.ai/vi/77103-2/Medxy AIvi2026-09-21T15:42:25-07:00 https://news.medxy.ai/zh/chronic-hepatitis-b/Medxy AIzh2026-09-21T15:41:16-07:00重新审视慢性乙型肝炎的免疫耐受期：RADICAL联盟揭示高转归率及其临床启示 https://news.medxy.ai/ja/chronic-hepatitis-b/Medxy AIja2026-09-21T15:40:55-07:00慢性B型肝炎の免疫寛容期を再考する：免疫活性病態への高い移行率とRADICAL consortiumが示す臨床的示唆 https://news.medxy.ai/vi/immune-tolerance-hepatitis-b/Medxy AIvi2026-09-21T15:40:33-07:00Xem xét lại pha dung nạp miễn dịch trong viêm gan B mạn tính: Tỷ lệ chuyển cao sang bệnh hoạt động miễn dịch và ý nghĩa lâm sàng từ liên minh RADICAL https://news.medxy.ai/zh/epilepsy-cause-evaluation/Medxy AIzh2026-09-21T15:39:34-07:00优化癫痫持续状态后的病因学评估：来自ICTAL登记研究的诊断获益与治疗启示 https://news.medxy.ai/ja/optimize-epilepsy-diagnosis/Medxy AIja2026-09-21T15:39:17-07:00けいれん重積状態後の病因検索を最適化する：ICTALレジストリが示す診断的有用性と治療への影響 https://news.medxy.ai/vi/epilepsy-investigation-optimization/Medxy AIvi2026-09-21T15:38:55-07:00Tối ưu hóa thăm dò căn nguyên sau trạng thái động kinh: Giá trị chẩn đoán và ý nghĩa điều trị từ sổ đăng ký ICTAL https://news.medxy.ai/ja/77090-2/Medxy AIja2026-09-21T15:37:32-07:00 https://news.medxy.ai/vi/harmonious-image-reading/Medxy AIvi2026-09-21T15:37:12-07:00Một khung đọc hình ảnh hài hòa để phân giai đoạn Tau PET trong bệnh Alzheimer https://news.medxy.ai/ja/quantitative-insights/Medxy AIja2026-09-21T15:34:57-07:00縦断的システムモデリングで読み解くチルゼパチドとセマグルチドの定量的知見 https://news.medxy.ai/vi/tirzepatide-semaglutide-power/Medxy AIvi2026-09-21T15:34:40-07:00Tiết lộ sức mạnh của Tirzepatide và Semaglutide qua mô hình hệ thống dọc https://news.medxy.ai/zh/77077-2/Medxy AIzh2026-09-21T15:33:44-07:00 https://news.medxy.ai/ja/brain-metabolism-biomarkers/Medxy AIja2026-09-21T15:33:23-07:00神経由来細胞外小胞バイオマーカーから読む脳代謝：CNSインスリン抵抗性におけるPPARγ作動薬とGLP1受容体作動薬の役割 https://news.medxy.ai/vi/neuron-exosome-biomarkers/Medxy AIvi2026-09-21T15:32:59-07:00Dấu ấn sinh học từ túi ngoại bào nguồn gốc neuron: PPARγ và chất chủ vận thụ thể GLP1 điều biến chuyển hóa não trong kháng insulin của CNS https://news.medxy.ai/zh/pediatric-thyroid-cancer/Medxy AIzh2026-09-21T15:31:45-07:00儿童分化型甲状腺癌：来自儿童与青少年甲状腺联盟的侵袭性疾病预测因素及治疗结局洞见 https://news.medxy.ai/ja/pediatric-thyroid-cancer/Medxy AIja2026-09-21T15:31:28-07:00小児分化型甲状腺癌：CATCが示す浸潤性病変の予測因子と治療成績 https://news.medxy.ai/vi/differentiated-thyroid-cancer-children/Medxy AIvi2026-09-21T15:31:06-07:00Ung thư tuyến giáp biệt hóa ở trẻ em: phát hiện từ Child and Adolescent Thyroid Consortium về các yếu tố dự báo bệnh xâm lấn và kết quả điều trị https://news.medxy.ai/zh/type-1-diabetes-risk/Medxy AIzh2026-09-21T15:30:08-07:001型糖尿病发病年龄越早，死亡与并发症风险越高：来自瑞典全国队列的研究启示 https://news.medxy.ai/ja/type-1-diabetes-age-onset/Medxy AIja2026-09-21T15:29:50-07:001型糖尿病は何歳で発症したかが予後を左右する：スウェーデン全国コホートが示す死亡・臓器合併症への影響 https://news.medxy.ai/vi/type-1-diabetes-age/Medxy AIvi2026-09-21T15:29:28-07:00Tuổi khởi phát đái tháo đường týp 1: yếu tố quyết định tiên lượng tử vong và biến chứng cơ quan từ dữ liệu đoàn hệ toàn quốc Thụy Điển https://news.medxy.ai/zh/empagliflozin-cv-benefits/Medxy AIzh2026-09-21T15:28:24-07:00恩格列净在2型糖尿病不同患者亚组中均显示一致的心血管获益：EMPRISE真实世界研究启示 https://news.medxy.ai/ja/empagliflozin-cv-benefits/Medxy AIja2026-09-21T15:28:04-07:00エンパグリフロジンは2型糖尿病の多様な患者集団で一貫した心血管利益を示す：EMPRISEリアルワールド研究からの知見 https://news.medxy.ai/vi/77045-2/Medxy AIvi2026-09-21T15:27:44-07:00 https://news.medxy.ai/zh/ttn-truncation-screening/Medxy AIzh2026-09-21T15:26:43-07:00携带TTN截断变异亲属的个体化筛查间隔：优化扩张型心肌病管理 https://news.medxy.ai/ja/ttn-mutation-screening/Medxy AIja2026-09-21T15:26:26-07:00TTN切断変異保有家族のスクリーニング間隔を個別化：拡張型心筋症管理の精緻化 https://news.medxy.ai/vi/77035-2/Medxy AIvi2026-09-21T15:26:07-07:00 https://news.medxy.ai/zh/elderly-heart-transplant-quality/Medxy AIzh2026-09-21T15:25:07-07:00老年患者接受心脏移植或机械循环支持后的长期生活质量结局：来自 SUSTAIN-IT 研究的启示 https://news.medxy.ai/ja/77028-2/Medxy AIja2026-09-21T15:24:50-07:00 https://news.medxy.ai/vi/77027-2/Medxy AIvi2026-09-21T15:24:32-07:00 https://news.medxy.ai/zh/clonal-hematopoiesis-hfpef/Medxy AIzh2026-09-21T15:23:37-07:00借助克隆性造血蛋白组学特征预测HFpEF预后 https://news.medxy.ai/ja/clonal-hematopoiesis-hfpef/Medxy AIja2026-09-21T15:23:17-07:00HFpEFの予後予測に挑むクローン性造血プロテオームシグネチャーの活用 https://news.medxy.ai/vi/hematopoiesis-proteome-hfpef/Medxy AIvi2026-09-21T15:22:54-07:00Khai thác dấu ấn proteome của tạo máu dòng vô tính để dự đoán tiên lượng trong HFpEF https://news.medxy.ai/zh/laennec-robotic-liver-surgery/Medxy AIzh2026-09-21T06:59:37-07:00Laennec技术：推动右侧机器人供肝切除标准化的新路径 https://news.medxy.ai/ja/76098-2/Medxy AIja2026-09-21T06:59:19-07:00ラエンネック（Laennec）法：ロボット支援下右側ドナー肝切除の標準化を推進する新たなアプローチ https://news.medxy.ai/vi/laennec-robotic-right-hepatectomy/Medxy AIvi2026-09-21T06:58:58-07:00Kỹ thuật Laennec: Hướng tới chuẩn hóa cắt gan phải ở người hiến bằng robot https://news.medxy.ai/the-laennec-technique-advancing-standardization-in-right-robotic-donor-hepatectomies/Medxy AIen2026-09-21T06:58:35-07:00The Laennec Technique: Advancing Standardization in Right Robotic Donor Hepatectomies https://news.medxy.ai/zh/robotic-left-pancreatectomy/Medxy AIzh2026-09-21T06:57:58-07:00机器人辅助左侧胰腺切除术学习曲线评估：一项国际多中心研究中的安全性与肿瘤学结局 https://news.medxy.ai/ja/robotic-left-pancreatectomy-2/Medxy AIja2026-09-21T06:57:38-07:00ロボット支援左側膵切除術の学習曲線を検証する：国際多施設研究による安全性と腫瘍学的転帰 https://news.medxy.ai/vi/robotic-left-pancreatectomy-learning-curve/Medxy AIvi2026-09-21T06:57:09-07:00Đánh giá đường cong học tập của cắt tụy trái hỗ trợ bằng robot: an toàn và kết cục ung bướu trong một nghiên cứu đa trung tâm quốc tế https://news.medxy.ai/assessing-the-learning-curve-of-robotic-left-sided-pancreatectomy-safety-and-oncological-outcomes-in-a-multicenter-international-study/Medxy AIen2026-09-21T06:56:47-07:00Assessing the Learning Curve of Robotic Left-Sided Pancreatectomy: Safety and Oncological Outcomes in a Multicenter International Study https://news.medxy.ai/zh/reduce-coronary-perfusion-risk/Medxy AIzh2026-09-21T06:56:03-07:00降低生物瓣主动脉根部置换中冠状动脉灌注不良风险的策略 https://news.medxy.ai/ja/coronary-flow-strategy/Medxy AIja2026-09-21T06:55:38-07:00生体人工弁大動脈基部置換における冠灌流障害を抑える戦略 https://news.medxy.ai/vi/reducing-coronary-ischemia/Medxy AIvi2026-09-21T06:55:12-07:00Chiến lược giảm thiểu thiếu máu tưới máu vành trong thay gốc động mạch chủ bằng van sinh học https://news.medxy.ai/strategies-to-minimize-coronary-malperfusion-in-bioprosthetic-aortic-root-replacement/Medxy AIen2026-09-21T06:54:48-07:00Strategies to Minimize Coronary Malperfusion in Bioprosthetic Aortic Root Replacement https://news.medxy.ai/zh/trauma-communication-gap/Medxy AIzh2026-09-21T06:54:04-07:00创伤救治中的沟通鸿沟：评估创伤复苏室内的创伤知情沟通 https://news.medxy.ai/ja/trauma-informed-communication/Medxy AIja2026-09-21T06:53:46-07:00外傷ベイにおけるトラウマ配慮型コミュニケーションを検証する：外傷ケアのギャップを埋める視点 https://news.medxy.ai/vi/trauma-care-communication/Medxy AIvi2026-09-21T06:53:20-07:00Thu hẹp khoảng cách trong chăm sóc chấn thương: Đánh giá giao tiếp theo hướng lưu ý đến sang chấn tại khu cấp cứu chấn thương https://news.medxy.ai/bridging-gaps-in-trauma-care-assessing-trauma-informed-communication-in-the-trauma-bay/Medxy AIen2026-09-21T06:52:55-07:00Bridging Gaps in Trauma Care: Assessing Trauma-Informed Communication in the Trauma Bay https://news.medxy.ai/zh/robotic-vs-laparoscopic-cholecystectomy-2/Medxy AIzh2026-09-21T06:52:11-07:00机器人胆囊切除术还是腹腔镜胆囊切除术？安全性、疗效与成本的权衡及新型风险计算器 https://news.medxy.ai/ja/robotic-vs-laparoscopic/Medxy AIja2026-09-21T06:51:51-07:00ロボット支援か腹腔鏡下か：新規リスク算出ツールでみる胆嚢摘出術の安全性・有効性・費用の最適な釣り合い https://news.medxy.ai/vi/robotic-gallbladder-surgery-2/Medxy AIvi2026-09-21T06:51:24-07:00Cắt túi mật bằng robot hay nội soi: Cân bằng an toàn, hiệu quả và chi phí với một công cụ dự đoán nguy cơ mới https://news.medxy.ai/robotic-versus-laparoscopic-cholecystectomy-balancing-safety-efficacy-and-cost-with-a-novel-risk-calculator/Medxy AIen2026-09-21T06:51:03-07:00Robotic Versus Laparoscopic Cholecystectomy: Balancing Safety, Efficacy, and Cost with a Novel Risk Calculator https://news.medxy.ai/zh/opioid-prescription-optimization/Medxy AIzh2026-09-21T06:50:21-07:00腹腔癌症术后阿片类药物出院处方如何优化：5倍乘数模型与三层模型的比较 https://news.medxy.ai/ja/optimize-opioid-prescription/Medxy AIja2026-09-21T06:50:03-07:00腹腔内がん手術後の退院時オピオイド処方を最適化する：5倍乗数モデルと3段階モデルの比較 https://news.medxy.ai/vi/opioid-prescription-optimization-2/Medxy AIvi2026-09-21T06:49:41-07:00Tối ưu hóa kê đơn opioid sau phẫu thuật ung thư trong ổ bụng: So sánh mô hình nhân 5 và mô hình 3 bậc https://news.medxy.ai/optimizing-postoperative-opioid-prescriptions-after-intra-abdominal-cancer-surgery-comparing-the-5x-multiplier-and-3-tier-models/Medxy AIen2026-09-21T06:49:23-07:00Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models https://news.medxy.ai/zh/rhd-antibody-formation/Medxy AIzh2026-09-21T06:48:45-07:00Rh(D) 阳性全血与 Rh(D) 阴性红细胞：创伤复苏后早期同种抗体形成的发生率及其意义 https://news.medxy.ai/ja/rh-positive-vs-rh-negative-blood/Medxy AIja2026-09-21T06:48:19-07:00外傷蘇生におけるRh(D)陽性全血とRh(D)陰性赤血球製剤：早期同種抗体形成の発生率と臨床的意義 https://news.medxy.ai/vi/antibody-formation-rates/Medxy AIvi2026-09-21T06:47:55-07:00Tỷ lệ và ý nghĩa của sự hình thành kháng thể bất đồng nhóm sớm sau hồi sức chấn thương bằng máu toàn phần Rh(D)+ so với hồng cầu Rh(D)- https://news.medxy.ai/incidence-and-implications-of-early-alloantibody-formation-after-trauma-resuscitation-with-rhd-whole-blood-versus-rhd-red-blood-cells/Medxy AIen2026-09-21T06:47:32-07:00Incidence and Implications of Early Alloantibody Formation After Trauma Resuscitation With Rh(D)+ Whole Blood Versus Rh(D)- Red Blood Cells https://news.medxy.ai/zh/gist-exon11-surgery/Medxy AIzh2026-09-21T06:46:47-07:00KIT 外显子 11 突变型 GIST 何时手术更合适？新辅助伊马替尼后影像学与病理学反应的启示 https://news.medxy.ai/ja/optimal-surgery-timing-gist/Medxy AIja2026-09-21T06:46:24-07:00KIT exon 11変異GISTにおける最適手術時期：ネオアジュバントimatinib後の画像評価と病理統合評価からみた示唆 https://news.medxy.ai/vi/optimal-gist-surgery/Medxy AIvi2026-09-21T06:45:55-07:00Thời điểm phẫu thuật tối ưu trong GIST đột biến KIT exon 11: Góc nhìn từ đáp ứng tích hợp hình ảnh và giải phẫu bệnh sau imatinib tân bổ trợ https://news.medxy.ai/optimal-surgical-timing-in-kit-exon-11-mutant-gist-insights-from-radiographic-and-pathology-integrated-responses-after-neoadjuvant-imatinib/Medxy AIen2026-09-21T06:45:31-07:00Optimal Surgical Timing in KIT Exon 11-Mutant GIST: Insights from Radiographic and Pathology-Integrated Responses After Neoadjuvant Imatinib https://news.medxy.ai/zh/avutometinib-defactinib-safety/Medxy AIzh2026-09-21T06:44:49-07:00复发性低级别浆液性卵巢癌中 Avutometinib 联合 Defactinib 的持久疗效与安全性：基于 ENGOT-OV60/GOG-3052/RAMP 201 2 年随访的解析 https://news.medxy.ai/ja/avutometinib-defactinib-ovarian-cancer/Medxy AIja2026-09-21T06:44:26-07:00再発低悪性度漿液性卵巣癌に対するAvutometinib＋Defactinibの持続的有効性と安全性：ENGOT-OV60/GOG-3052/RAMP 201の2年追跡解析 https://news.medxy.ai/vi/76057-2/Medxy AIvi2026-09-21T06:44:01-07:00Hiệu quả lâu dài và độ an toàn của Avutometinib kết hợp với Defactinib trong điều trị ung thư buồng trứng thể tuyến thanh dịch độ thấp tái phát: Phân tích dựa trên theo dõi 2 năm từ nghiên cứu ENGOT-OV60/GOG-3052/RAMP 201 https://news.medxy.ai/durable-efficacy-and-safety-of-avutometinib-plus-defactinib-in-recurrent-low-grade-serous-ovarian-cancer-insights-from-a-2-year-engot-ov60-gog-3052-ramp-201-follow-up/Medxy AIen2026-09-21T06:43:33-07:00Durable Efficacy and Safety of Avutometinib plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Insights from a 2-Year ENGOT-OV60/GOG-3052/RAMP 201 Follow-up https://news.medxy.ai/zh/liver-cirrhosis-fall-prevention/Medxy AIzh2026-09-21T06:42:42-07:00乳果糖序贯联用 TeleTai-Chi：肝硬化患者跌倒预防的新策略 https://news.medxy.ai/ja/fall-prevention-cirrhosis/Medxy AIja2026-09-21T06:42:21-07:00肝硬変の転倒予防に挑む：ラクツロースと TeleTai-Chi を段階的に用いた LiveSMART 試験の知見 https://news.medxy.ai/vi/76052-2/Medxy AIvi2026-09-21T06:41:58-07:00Sử dụng tuần tự Lactulose và Tele-Tai Chi: Một chiến lược mới nhằm phòng ngừa té ngã ở bệnh nhân xơ gan https://news.medxy.ai/sequential-lactulose-and-teletai-chi-to-prevent-falls-in-cirrhosis-insights-from-the-livesmart-trial/Medxy AIen2026-09-21T06:41:31-07:00Sequential Lactulose and TeleTai-Chi to Prevent Falls in Cirrhosis: Insights from the LiveSMART Trial https://news.medxy.ai/zh/gut-microbiome-liver-cancer-2/Medxy AIzh2026-09-21T06:40:43-07:00肠道微生物组动态变化有望提升晚期肝癌免疫治疗获益预测 https://news.medxy.ai/ja/gut-microbiome-liver-cancer/Medxy AIja2026-09-21T06:40:22-07:00進行性肝癌の免疫療法成績を高める腸内マイクロバイオームの動的変化 https://news.medxy.ai/vi/gut-microbiome-therapy/Medxy AIvi2026-09-21T06:39:56-07:00Biến đổi động của hệ vi sinh đường ruột giúp nâng cao kết quả miễn dịch trị liệu ở ung thư gan giai đoạn tiến xa https://news.medxy.ai/dynamic-gut-microbiome-changes-enhance-immunotherapy-outcomes-in-advanced-liver-cancer/Medxy AIen2026-09-21T06:39:29-07:00Dynamic Gut Microbiome Changes Enhance Immunotherapy Outcomes in Advanced Liver Cancer https://news.medxy.ai/zh/hbv-immunosuppressive-macrophages/Medxy AIzh2026-09-21T06:38:48-07:00HBV诱导的免疫抑制性巨噬细胞：驱动慢性乙型肝炎持续存在的代谢与表观遗传通路 https://news.medxy.ai/ja/hbv-induced-macrophages/Medxy AIja2026-09-21T06:38:24-07:00HBVが誘導する免疫抑制性マクロファージ：慢性B型肝炎の持続を支える代謝・エピジェネティック経路 https://news.medxy.ai/vi/76042-2/Medxy AIvi2026-09-21T06:37:58-07:00Đại thực bào ức chế miễn dịch do HBV: Các con đường chuyển hóa và biểu di truyền thúc đẩy sự tồn tại dai dẳng của viêm gan B mạn tính https://news.medxy.ai/hbv-induced-immunosuppressive-macrophages-metabolic-and-epigenetic-pathways-driving-chronic-hepatitis-b-persistence/Medxy AIen2026-09-21T06:37:29-07:00HBV-Induced Immunosuppressive Macrophages: Metabolic and Epigenetic Pathways Driving Chronic Hepatitis B Persistence https://news.medxy.ai/zh/pancreatitis-pain-treatment/Medxy AIzh2026-09-21T06:36:44-07:00非肠溶包衣胰酶治疗慢性胰腺炎疼痛：一项高质量随机试验带来的启示 https://news.medxy.ai/ja/pancreatitis-pain-relief/Medxy AIja2026-09-21T06:36:20-07:00慢性膵炎の疼痛緩和に対する非腸溶性膵酵素療法を検証する：堅牢な無作為化試験からの知見 https://news.medxy.ai/vi/pancreatic-enzyme-therapy-pain/Medxy AIvi2026-09-21T06:35:53-07:00Đánh giá liệu pháp enzym tụy không bao tan ruột trong giảm đau do viêm tụy mạn: dữ liệu từ một thử nghiệm ngẫu nhiên quy mô lớn https://news.medxy.ai/evaluating-non-enteric-coated-pancreatic-enzyme-therapy-for-pain-relief-in-chronic-pancreatitis-insights-from-a-robust-randomized-trial/Medxy AIen2026-09-21T06:35:30-07:00Evaluating Non-Enteric-Coated Pancreatic Enzyme Therapy for Pain Relief in Chronic Pancreatitis: Insights from a Robust Randomized Trial https://news.medxy.ai/zh/microbiome-therapy-advances/Medxy AIzh2026-09-21T06:34:46-07:00精准微生物组治疗新进展：Faecalibacterium prausnitzii EXL01 预防多次复发性艰难拟梭菌感染 https://news.medxy.ai/ja/microbiome-treatment-clostridioides-prevention/Medxy AIja2026-09-21T06:34:21-07:00精密マイクロバイオーム治療の新展開：多発再発性 Clostridioides difficile 感染症予防における Faecalibacterium prausnitzii EXL01 https://news.medxy.ai/vi/76032-2/Medxy AIvi2026-09-21T06:33:53-07:00Faecalibacterium prausnitzii EXL01 để phòng ngừa tái phát nhiễm khuẩn Clostridioides difficile https://news.medxy.ai/precision-microbiome-therapeutics-faecalibacterium-prausnitzii-exl01-for-prevention-of-multiple-recurrent-clostridioides-difficile-infection/Medxy AIen2026-09-21T06:33:27-07:00Precision Microbiome Therapeutics: Faecalibacterium prausnitzii EXL01 for Prevention of Multiple-Recurrent Clostridioides difficile Infection https://news.medxy.ai/zh/cdkl5-eeg-seizures/Medxy AIzh2026-09-21T06:32:23-07:00早期 CDKL5 缺陷障碍中的 EEG 演变与发作特征：对发育结局的启示 https://news.medxy.ai/ja/cdkl5-eeg-seizures-2/Medxy AIja2026-09-21T06:31:59-07:00CDKL5欠損症乳幼児におけるEEGの推移と発作特徴：発達予後への示唆 https://news.medxy.ai/vi/cdkl5-seizure-progress/Medxy AIvi2026-09-21T06:31:34-07:00Diễn tiến EEG và đặc điểm cơn co giật trong giai đoạn sớm của rối loạn thiếu hụt CDKL5: hàm ý đối với kết cục phát triển https://news.medxy.ai/eeg-evolution-and-seizure-characteristics-in-early-cdkl5-deficiency-disorder-implications-for-developmental-outcomes/Medxy AIen2026-09-21T06:31:11-07:00EEG Evolution and Seizure Characteristics in Early CDKL5 Deficiency Disorder: Implications for Developmental Outcomes https://news.medxy.ai/zh/veterans-explosion-health/Medxy AIzh2026-09-21T06:30:27-07:00退伍军人军事爆炸暴露的长期健康影响：来自 Millennium Cohort Study 的启示 https://news.medxy.ai/ja/military-blast-exposure-risks/Medxy AIja2026-09-21T06:30:04-07:00軍務中の爆風曝露は退役後の健康にどう影響するか：ミレニアム・コホート研究が示す長期的リスク https://news.medxy.ai/vi/long-term-health-effects/Medxy AIvi2026-09-21T06:29:37-07:00Ảnh hưởng sức khỏe lâu dài của phơi nhiễm nổ trong quân đội ở cựu chiến binh: Những phát hiện từ Millennium Cohort Study https://news.medxy.ai/long-term-health-impacts-of-military-blast-exposure-on-veterans-insights-from-the-millennium-cohort-study/Medxy AIen2026-09-21T06:29:12-07:00Long-Term Health Impacts of Military Blast Exposure on Veterans: Insights from the Millennium Cohort Study https://news.medxy.ai/zh/pituitary-adenoma-subtypes/Medxy AIzh2026-09-21T06:28:30-07:00垂体腺瘤的组织学亚型：对肢端肥大症手术结局与疾病控制的影响 https://news.medxy.ai/ja/pituitary-adenoma-subtypes-2/Medxy AIja2026-09-21T06:28:04-07:00下垂体腺腫の組織学的サブタイプ：先端巨大症における手術成績と疾患コントロールへの影響 https://news.medxy.ai/vi/pituitary-adenoma-classification/Medxy AIvi2026-09-21T06:27:38-07:00Phân nhóm mô học của u tuyến yên: Vai trò trong kết cục phẫu thuật và kiểm soát bệnh ở bệnh to đầu chi https://news.medxy.ai/histological-subtypes-of-pituitary-adenomas-their-role-in-acromegaly-surgical-outcomes-and-disease-control/Medxy AIen2026-09-21T06:27:09-07:00Histological Subtypes of Pituitary Adenomas: Their Role in Acromegaly Surgical Outcomes and Disease Control https://news.medxy.ai/zh/anaplastic-thyroid-cancer-chemotherapy/Medxy AIzh2026-09-21T06:26:22-07:00德国多中心注册研究：间变性甲状腺癌一线化疗策略的疗效评估 https://news.medxy.ai/ja/undifferentiated-thyroid-cancer-chemotherapy/Medxy AIja2026-09-21T06:25:59-07:00未分化甲状腺がんの一次化学療法を再考する：ドイツ多施設レジストリからの知見 https://news.medxy.ai/vi/thyroid-cancer-treatment-2/Medxy AIvi2026-09-21T06:25:37-07:00Đánh giá chiến lược hóa trị tuyến đầu trong ung thư tuyến giáp không biệt hóa: Góc nhìn từ một đăng ký đa trung tâm tại Đức https://news.medxy.ai/evaluating-first-line-chemotherapy-strategies-in-anaplastic-thyroid-cancer-insights-from-a-german-multicenter-registry/Medxy AIen2026-09-21T06:25:15-07:00Evaluating First-Line Chemotherapy Strategies in Anaplastic Thyroid Cancer: Insights from a German Multicenter Registry https://news.medxy.ai/zh/cushing-disease-remission/Medxy AIzh2026-09-21T06:24:27-07:00库欣病长期缓解后血浆蛋白异常仍持续存在：对发病风险与监测的启示 https://news.medxy.ai/ja/cushing-disease-biomarkers/Medxy AIja2026-09-21T06:24:02-07:00クッシング病の長期寛解後も残る血漿タンパク質異常――罹患リスクと経過観察への示唆 https://news.medxy.ai/vi/cushing-syndrome-longterm/Medxy AIvi2026-09-21T06:23:32-07:00Bệnh Cushing sau thuyên giảm lâu dài: các bất thường protein huyết tương dai dẳng và ý nghĩa đối với bệnh tật, theo dõi https://news.medxy.ai/persistent-plasma-protein-alterations-after-long-term-remission-in-cushings-disease-implications-for-morbidity-and-monitoring/Medxy AIen2026-09-21T06:23:07-07:00Persistent Plasma Protein Alterations After Long-Term Remission in Cushing’s Disease: Implications for Morbidity and Monitoring https://news.medxy.ai/zh/type-1-diabetes-trajectories/Medxy AIzh2026-09-21T06:22:20-07:001型糖尿病成人的长期血糖轨迹：一项3年多中心CGM研究的启示 https://news.medxy.ai/ja/type-1-diabetes-trends/Medxy AIja2026-09-21T06:21:56-07:001型糖尿病成人における血糖推移の縦断解析：3年間の多施設CGM研究からの示唆 https://news.medxy.ai/vi/vertical-glucose-trajectory/Medxy AIvi2026-09-21T06:21:29-07:00Quỹ đạo đường huyết theo chiều dọc ở người lớn mắc đái tháo đường típ 1: Góc nhìn từ nghiên cứu đa trung tâm CGM kéo dài 3 năm https://news.medxy.ai/longitudinal-glycemic-trajectories-in-adults-with-type-1-diabetes-insights-from-a-three-year-multicenter-cgm-study/Medxy AIen2026-09-21T06:21:04-07:00Longitudinal Glycemic Trajectories in Adults with Type 1 Diabetes: Insights from a Three-Year Multicenter CGM Study https://news.medxy.ai/zh/pregnancy-pcos-outcomes/Medxy AIzh2026-09-21T06:20:15-07:00妊娠期多内分泌代谢性卵巢综合征与母婴结局：一项嵌套前瞻性队列研究的启示 https://news.medxy.ai/ja/pcos-pregnancy-effects/Medxy AIja2026-09-21T06:19:52-07:00妊娠中のポリ内分泌代謝性卵巣症候群が母体・新生児転帰に及ぼす影響：ネスト型前向きコホート研究からの知見 https://news.medxy.ai/vi/75973-2/Medxy AIvi2026-09-21T06:19:22-07:00Hội chứng buồng trứng đa nang trong thai kỳ và kết cục đối với mẹ và con https://news.medxy.ai/maternal-and-neonatal-outcomes-associated-with-polyendocrine-metabolic-ovarian-syndrome-during-pregnancy-insights-from-a-nested-prospective-cohort-study/Medxy AIen2026-09-21T06:18:57-07:00Maternal and Neonatal Outcomes Associated with Polyendocrine Metabolic Ovarian Syndrome During Pregnancy: Insights from a Nested Prospective Cohort Study https://news.medxy.ai/zh/diabetes-management-alerts/Medxy AIzh2026-09-21T06:18:10-07:00从预警到行动：借助电子健康记录提醒提升糖尿病自我管理转诊 https://news.medxy.ai/ja/alert-action-diabetes/Medxy AIja2026-09-21T06:17:50-07:00アラートを行動へ：電子カルテのアラートで糖尿病自己管理支援紹介を強化する https://news.medxy.ai/vi/diabetes-care-alerts/Medxy AIvi2026-09-21T06:17:30-07:00Từ cảnh báo đến hành động: Nâng cao chuyển tuyến giáo dục tự quản lý đái tháo đường qua cảnh báo trên hồ sơ sức khỏe điện tử https://news.medxy.ai/from-alert-to-action-enhancing-diabetes-self-management-referrals-through-electronic-health-record-alerts/Medxy AIen2026-09-21T06:17:08-07:00From Alert to Action: Enhancing Diabetes Self-Management Referrals Through Electronic Health Record Alerts https://news.medxy.ai/zh/semaglutide-efficacy-safety/Medxy AIzh2026-09-21T06:16:28-07:00司美格鲁肽在不同虚弱状态下的疗效与安全性：基于SELECT随机临床试验事后分析的启示 https://news.medxy.ai/ja/semaglutide-efficacy-safety-2/Medxy AIja2026-09-21T06:16:02-07:00フレイル状態別にみたセマグルチドの有効性と安全性：SELECTランダム化臨床試験の事後解析からの示唆 https://news.medxy.ai/vi/semaglutide-frailty/Medxy AIvi2026-09-21T06:15:33-07:00Semaglutide: Hiệu quả và độ an toàn theo tình trạng frailty từ phân tích hậu kiểm thử nghiệm lâm sàng ngẫu nhiên SELECT https://news.medxy.ai/efficacy-and-safety-of-semaglutide-according-to-frailty-status-insights-from-the-select-randomized-clinical-trial-post-hoc-analysis/Medxy AIen2026-09-21T06:15:04-07:00Efficacy and Safety of Semaglutide According to Frailty Status: Insights from the SELECT Randomized Clinical Trial Post Hoc Analysis https://news.medxy.ai/ja/whole-grains-metabolic-risk/Medxy AIja2026-09-21T05:46:13-07:00全粒穀物の摂取は心代謝リスクを下げるか：ランダム化試験のメタ解析 https://news.medxy.ai/vi/whole-grains-heart-risk/Medxy AIvi2026-09-21T05:45:50-07:00Ngũ cốc nguyên hạt và nguy cơ tim mạch – chuyển hóa: Phân tích tổng hợp từ các thử nghiệm ngẫu nhiên https://news.medxy.ai/whole-grain-consumption-and-cardiometabolic-risk-a-meta-analysis-of-randomized-trials/Medxy AIen2026-09-21T05:45:25-07:00Whole-grain Consumption and Cardiometabolic Risk: A Meta-analysis of Randomized Trials https://news.medxy.ai/zh/75928-2/Medxy AIzh2026-09-21T05:44:35-07:00心脏压力负荷时代谢应激可能加剧蒽环类药物的心脏毒性 https://news.medxy.ai/ja/anthracycline-cardiotoxicity/Medxy AIja2026-09-21T05:44:02-07:00圧負荷心における代謝ストレスが増幅するアントラサイクリン心毒性：機序的理解と臨床的意義 https://news.medxy.ai/vi/anthracycline-heart-toxicity/Medxy AIvi2026-09-21T05:43:35-07:00Độc tính tim do anthracycline bị thúc đẩy bởi stress chuyển hóa ở tim quá tải áp lực: cơ chế và ý nghĩa lâm sàng https://news.medxy.ai/anthracycline-cardiotoxicity-exacerbated-by-metabolic-stress-in-pressure-overloaded-hearts-mechanistic-insights-and-clinical-implications/Medxy AIen2026-09-21T05:43:03-07:00Anthracycline Cardiotoxicity Exacerbated by Metabolic Stress in Pressure-Overloaded Hearts: Mechanistic Insights and Clinical Implications https://news.medxy.ai/zh/hpv16-head-neck-cancer/Medxy AIzh2026-09-21T05:42:19-07:00HPV16 阳性复发/转移性头颈癌迎来新希望：VERSATILE-002Ⅱ期研究揭示免疫联合治疗潜力 https://news.medxy.ai/ja/hpv16-recurrence-treatment/Medxy AIja2026-09-21T05:41:57-07:00HPV16陽性再発・転移性頭頸部癌で新規免疫療法併用に期待：VERSATILE-002第2相試験から見えた可能性 https://news.medxy.ai/vi/immune-combination-hpv16/Medxy AIvi2026-09-21T05:41:28-07:00Phối hợp miễn dịch mới cho kết quả khả quan ở ung thư đầu cổ tái phát/di căn dương tính HPV16: Góc nhìn từ thử nghiệm pha 2 VERSATILE-002 https://news.medxy.ai/novel-immunotherapy-combination-shows-promise-in-hpv16-positive-r-m-head-and-neck-cancer-insights-from-the-versatile-002-phase-2-trial/Medxy AIen2026-09-21T05:41:02-07:00Novel Immunotherapy Combination Shows Promise in HPV16-Positive R/M Head and Neck Cancer: Insights from the VERSATILE-002 Phase 2 Trial https://news.medxy.ai/zh/low-pdl1-head-neck-cancer/Medxy AIzh2026-09-21T05:40:15-07:00低 PD-L1 表达头颈鳞状细胞癌的免疫治疗：一项关于生存结局的荟萃分析洞见 https://news.medxy.ai/ja/pd-l1-low-headneck-cancer/Medxy AIja2026-09-21T05:39:46-07:00PD-L1低発現頭頸部扁平上皮癌における免疫療法：生存転帰を読み解くメタ解析の知見 https://news.medxy.ai/vi/75916-2/Medxy AIvi2026-09-21T05:39:12-07:00Liệu pháp miễn dịch trong ung thư biểu mô tế bào vảy vùng đầu cổ có biểu hiện PD-L1 thấp https://news.medxy.ai/immunotherapy-in-head-and-neck-squamous-cell-carcinoma-with-low-pd-l1-expression-a-meta-analytic-insight-into-survival-outcomes/Medxy AIen2026-09-21T05:38:48-07:00Immunotherapy in Head and Neck Squamous Cell Carcinoma with Low PD-L1 Expression: A Meta-Analytic Insight into Survival Outcomes https://news.medxy.ai/zh/at2-tgf-beta1-platelet-thrombosis/Medxy AIzh2026-09-21T05:14:03-07:00揭示血管紧张素Ⅱ驱动的TGF-β1在高血压中增强血小板PAR4表达及血栓风险中的作用 https://news.medxy.ai/ja/angiotensin-tgf-beta-thrombosis/Medxy AIja2026-09-21T05:13:42-07:00アンジオテンシンII―TGF-β1軸が血小板PAR4を高める機序と高血圧における血栓リスクの新知見 https://news.medxy.ai/vi/tgf-beta1-par4-thrombosis/Medxy AIvi2026-09-21T05:13:19-07:00Khám phá vai trò của TGF-β1 do Angiotensin II dẫn dắt trong việc làm tăng biểu hiện PAR4 trên tiểu cầu và nguy cơ huyết khối ở tăng huyết áp https://news.medxy.ai/angiotensin-tgf-beta-thrombosis-2/Medxy AIen2026-09-21T05:12:54-07:00Unveiling the Role of Angiotensin II-Driven TGF-β1 in Enhancing Platelet PAR4 Expression and Thrombotic Risk in Hypertension https://news.medxy.ai/zh/low-dose-rivaroxaban/Medxy AIzh2026-09-20T09:24:56-07:00重度慢性肾脏病合并高心血管风险患者低剂量利伐沙班的疗效与安全性：综合综述 https://news.medxy.ai/ja/low-dose-rivaroxaban-ckd/Medxy AIja2026-09-20T09:24:31-07:00高心血管リスクを伴う進行期慢性腎臓病における低用量リバーロキサバンの有効性と安全性：包括的レビュー https://news.medxy.ai/vi/75900-2/Medxy AIvi2026-09-20T09:24:05-07:00Hiệu quả và độ an toàn của rivaroxaban liều thấp ở bệnh nhân mắc bệnh thận mạn giai đoạn tiến triển và có nguy cơ tim mạch cao https://news.medxy.ai/efficacy-and-safety-of-low-dose-rivaroxaban-in-advanced-chronic-kidney-disease-with-high-cardiovascular-risk-a-comprehensive-review/Medxy AIen2026-09-20T09:23:39-07:00Efficacy and Safety of Low-Dose Rivaroxaban in Advanced Chronic Kidney Disease with High Cardiovascular Risk: A Comprehensive Review https://news.medxy.ai/zh/pd-l1-pd-l2-b-cell-lymphoma-2/Medxy AIzh2026-09-20T09:22:45-07:00PD-L1与PD-L2在原发性纵隔大B细胞淋巴瘤中的不同作用：对免疫治疗的启示 https://news.medxy.ai/ja/pd-l1-pd-l2-roles/Medxy AIja2026-09-20T09:22:22-07:00原発性縦隔大細胞型B細胞リンパ腫におけるPD-L1とPD-L2の異なる役割：免疫治療への示唆 https://news.medxy.ai/vi/pd-l1-pd-l2-b-cell-lymphoma/Medxy AIvi2026-09-20T09:21:57-07:00Vai trò khác biệt của PD-L1 và PD-L2 trong u lympho tế bào B lớn nguyên phát trung thất: hàm ý cho miễn dịch trị liệu https://news.medxy.ai/distinct-roles-of-pd-l1-and-pd-l2-in-primary-mediastinal-large-b-cell-lymphoma-implications-for-immune-therapeutics/Medxy AIen2026-09-20T09:21:34-07:00Distinct Roles of PD-L1 and PD-L2 in Primary Mediastinal Large B-Cell Lymphoma: Implications for Immune Therapeutics https://news.medxy.ai/zh/neutrophil-driven-hemophilic-arthritis/Medxy AIzh2026-09-20T09:20:46-07:00中性粒细胞驱动的血友病性关节病干扰素病变：潜在新靶点的揭示 https://news.medxy.ai/ja/hemophilic-arthritis-research/Medxy AIja2026-09-20T09:20:25-07:00血友病性関節症における好中球駆動型インターフェロン病の解明：新たな治療標的 https://news.medxy.ai/vi/interferonopathy-treatment/Medxy AIvi2026-09-20T09:19:55-07:00Giải mã interferonopathy do bạch cầu trung tính trong bệnh khớp do máu khó đông: một đích điều trị mới https://news.medxy.ai/unraveling-neutrophil-driven-interferonopathy-in-hemophilic-arthropathy-a-new-therapeutic-target/Medxy AIen2026-09-20T09:19:28-07:00Unraveling Neutrophil-Driven Interferonopathy in Hemophilic Arthropathy: A New Therapeutic Target https://news.medxy.ai/zh/mycobacterium-massiliense/Medxy AIzh2026-09-20T09:18:45-07:00东亚特异性 Mycobacterium massiliense ST120：系统发育基因组学、临床影响与肺部疾病管理挑战 https://news.medxy.ai/ja/mycobacterium-massiliense-east-asia/Medxy AIja2026-09-20T09:18:23-07:00東アジアに特有な Mycobacterium massiliense ST120：系統ゲノム解析、臨床的影響、そして肺疾患管理の課題 https://news.medxy.ai/vi/75872-2/Medxy AIvi2026-09-20T09:17:59-07:00Những thách thức trong việc quản lý bệnh phổi do chủng *Mycobacterium massiliense* ST120 đặc thù tại Đông Á gây ra https://news.medxy.ai/east-asia-specific-mycobacterium-massiliense-st120-phylogenomics-clinical-impact-and-challenges-in-pulmonary-disease-management/Medxy AIen2026-09-20T09:17:36-07:00East Asia-Specific Mycobacterium massiliense ST120: Phylogenomics, Clinical Impact, and Challenges in Pulmonary Disease Management https://news.medxy.ai/zh/lynx1-phase3-trial/Medxy AIzh2026-09-20T09:17:01-07:00LYNX-1 Ⅲ期试验：0.75%酚妥拉明滴眼液改善暗光视觉障碍 https://news.medxy.ai/ja/fentolamine-eye-drops/Medxy AIja2026-09-20T09:16:34-07:00暗所視障害に対する0.75%フェントラミン点眼液：第3相LYNX-1試験の結果 https://news.medxy.ai/vi/phentolamine-eye-drops/Medxy AIvi2026-09-20T09:16:06-07:00LYNX-1 giai đoạn 3: dung dịch nhỏ mắt phentolamine cho rối loạn thị giác khi ánh sáng yếu https://news.medxy.ai/lynx-1-phase-3-trial-phentolamine-ophthalmic-solution-for-dim-light-vision-disturbances/Medxy AIen2026-09-20T09:15:40-07:00LYNX-1 Phase 3 Trial: Phentolamine Ophthalmic Solution for Dim Light Vision Disturbances https://news.medxy.ai/zh/linc01521-thyroid-cancer/Medxy AIzh2026-09-20T09:14:52-07:00LINC01521 在乳头状甲状腺癌中的作用：预后价值与分子机制探析 https://news.medxy.ai/ja/linc01521-thyroid-cancer-3/Medxy AIja2026-09-20T09:14:29-07:00乳頭状甲状腺癌におけるLINC01521の役割を解明する：予後予測能と分子機序 https://news.medxy.ai/vi/linc01521-thyroid-cancer-2/Medxy AIvi2026-09-20T09:14:02-07:00LINC01521 trong ung thư biểu mô nhú tuyến giáp: ý nghĩa tiên lượng và cơ chế phân tử https://news.medxy.ai/unraveling-the-role-of-linc01521-in-papillary-thyroid-carcinoma-prognostic-potential-and-molecular-mechanisms/Medxy AIen2026-09-20T09:13:36-07:00Unraveling the Role of LINC01521 in Papillary Thyroid Carcinoma: Prognostic Potential and Molecular Mechanisms https://news.medxy.ai/zh/xenotransplantation-liver-failure/Medxy AIzh2026-09-20T09:12:48-07:00急性肝衰竭中的异种移植：以基因修饰猪肝弥合供肝缺口 https://news.medxy.ai/ja/xenotransplantation-liver-failure-2/Medxy AIja2026-09-20T09:12:25-07:00急性肝不全における異種移植：遺伝子改変ブタ肝臓が切り開く臓器ギャップへの橋渡し https://news.medxy.ai/vi/xenotransplantation-liver/Medxy AIvi2026-09-20T09:11:56-07:00Ghép dị loài gan trong suy gan cấp: thu hẹp khoảng cách thiếu hụt tạng ghép bằng gan lợn biến đổi gen https://news.medxy.ai/xenotransplantation-in-acute-liver-failure-bridging-the-organ-gap-with-genetically-modified-porcine-livers/Medxy AIen2026-09-20T09:11:30-07:00Xenotransplantation in Acute Liver Failure: Bridging the Organ Gap with Genetically Modified Porcine Livers https://news.medxy.ai/zh/gut-vascular-barrier/Medxy AIzh2026-09-20T09:10:49-07:00肠-血管屏障失守：巨噬细胞功能障碍如何推动肝硬化中的细菌移位 https://news.medxy.ai/ja/liver-cirrhosis-barrier-breakdown/Medxy AIja2026-09-20T09:10:25-07:00肝硬変における腸管―血管バリア破綻を読み解く：マクロファージ機能障害が細菌トランスロケーションを駆動する https://news.medxy.ai/vi/vascular-barrier-breakdown/Medxy AIvi2026-09-20T09:09:56-07:00Khi hàng rào ruột-mạch máu bị phá vỡ: Rối loạn đại thực bào thúc đẩy chuyển vị vi khuẩn trong xơ gan https://news.medxy.ai/dissecting-gut-vascular-barrier-failures-macrophage-dysfunction-drives-bacterial-translocation-in-cirrhosis/Medxy AIen2026-09-20T09:09:31-07:00Dissecting Gut-Vascular Barrier Failures: Macrophage Dysfunction Drives Bacterial Translocation in Cirrhosis https://news.medxy.ai/zh/postmenopausal-estradiol-range/Medxy AIzh2026-09-20T09:08:49-07:00绝经后女性雌二醇参考范围实现统一：提升激素评估与风险预测准确性的突破 https://news.medxy.ai/ja/75832-2/Medxy AIja2026-09-20T09:08:26-07:00閉経後女性のエストラジオール基準範囲が統一されました https://news.medxy.ai/vi/estradiol-reference-women/Medxy AIvi2026-09-20T09:08:02-07:00Chuẩn hóa khoảng tham chiếu estradiol ở phụ nữ sau mãn kinh: Bước tiến cho đánh giá hormone chính xác và dự đoán nguy cơ https://news.medxy.ai/harmonizing-estradiol-reference-ranges-in-postmenopausal-women-a-breakthrough-for-accurate-hormone-assessment-and-risk-prediction/Medxy AIen2026-09-20T09:07:36-07:00Harmonizing Estradiol Reference Ranges in Postmenopausal Women: A Breakthrough for Accurate Hormone Assessment and Risk Prediction https://news.medxy.ai/zh/adam10-atrial-fibrillation/Medxy AIzh2026-09-20T09:06:55-07:00乳腺癌来源ADAM10：通过心房纤维化介导心房颤动的新机制 https://news.medxy.ai/ja/adam10-atrial-fibrillation-2/Medxy AIja2026-09-20T09:06:31-07:00乳がん由来ADAM10が心房細動を誘発する新機序：心房線維化を介した腫瘍―心臓連関 https://news.medxy.ai/vi/adam10-breast-cancer/Medxy AIvi2026-09-20T09:06:04-07:00ADAM10 có nguồn gốc từ ung thư vú: tác nhân mới làm trung gian rung nhĩ qua xơ hóa nhĩ https://news.medxy.ai/breast-cancer-derived-adam10-a-novel-mediator-of-atrial-fibrillation-through-atrial-fibrosis/Medxy AIen2026-09-20T09:05:38-07:00Breast Cancer-Derived ADAM10: A Novel Mediator of Atrial Fibrillation Through Atrial Fibrosis https://news.medxy.ai/zh/retina-octa-insights/Medxy AIzh2026-09-20T08:57:34-07:00视网膜OCTA：洞察脑小血管病与卒中后认知下降的新窗口 https://news.medxy.ai/ja/75805-2/Medxy AIja2026-09-20T08:57:09-07:00網膜OCTA：脳小血管病と脳卒中後の認知機能低下を解明する新たな窓 https://news.medxy.ai/vi/75804-2/Medxy AIvi2026-09-20T08:56:44-07:00OCTA võng mạc: Một góc nhìn mới về bệnh lý mạch máu nhỏ não và suy giảm nhận thức sau đột quỵ https://news.medxy.ai/retinal-octa-as-a-window-into-cerebral-small-vessel-disease-and-cognitive-decline-post-stroke/Medxy AIen2026-09-20T08:56:15-07:00Retinal OCTA as a Window into Cerebral Small Vessel Disease and Cognitive Decline Post-Stroke https://news.medxy.ai/zh/relapse-b-cell-leukemia/Medxy AIzh2026-09-20T08:55:33-07:00复发/难治性 B 细胞急性淋巴细胞白血病成人首次挽救治疗的预后因素及异基因造血干细胞移植作用 https://news.medxy.ai/ja/b-cell-leukemia-treatment/Medxy AIja2026-09-20T08:55:09-07:00ブリナツモマブ／イノツズマブ オゾガマイシンを用いた初回救援療法における再発／難治性B細胞急性リンパ性白血病成人患者の予後因子と同種造血幹細胞移植の役割 https://news.medxy.ai/vi/allo-hsct-prognosis-b-all/Medxy AIvi2026-09-20T08:54:42-07:00Yếu tố tiên lượng và vai trò của allo-HSCT trong điều trị cứu vãn bậc một ở người lớn mắc B-ALL tái phát/kháng trị điều trị bằng blinatumomab và inotuzumab ozogamicin https://news.medxy.ai/prognostic-factors-and-role-of-allo-hsct-in-first-salvage-therapy-for-adults-with-relapsed-refractory-b-cell-acute-lymphoblastic-leukemia-treated-with-blinatumomab-and-inotuzumab-ozogamicin/Medxy AIen2026-09-20T08:54:17-07:00Prognostic Factors and Role of Allo-HSCT in First Salvage Therapy for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Blinatumomab and Inotuzumab Ozogamicin https://news.medxy.ai/zh/wean-failure-phenotypes-2/Medxy AIzh2026-09-20T08:51:31-07:00有创机械通气撤机失败的三种不同表型：来自WEAN SAFE队列的研究启示 https://news.medxy.ai/ja/wean-failure-phenotypes/Medxy AIja2026-09-20T08:51:11-07:00侵襲的人工呼吸離脱失敗にみられる3つの異なる表現型──WEAN SAFEコホートからの知見 https://news.medxy.ai/vi/wean-failure-types/Medxy AIvi2026-09-20T08:50:44-07:00Ba kiểu hình cai máy khác nhau ở bệnh nhân thất bại thở máy xâm nhập: phát hiện từ đoàn hệ WEAN SAFE https://news.medxy.ai/distinct-weaning-phenotypes-in-invasive-mechanical-ventilation-failures-insights-from-the-wean-safe-cohort/Medxy AIen2026-09-20T08:50:21-07:00Distinct Weaning Phenotypes in Invasive Mechanical Ventilation Failures: Insights from the WEAN SAFE Cohort https://news.medxy.ai/zh/75783-2/Medxy AIzh2026-09-20T08:49:45-07:00低剂量氯胺酮可减少ICU患者阿片类药物用量——一项针对机械通气患者的双盲随机试验结果 https://news.medxy.ai/ja/low-dose-ketamine-icu-opioids/Medxy AIja2026-09-20T08:49:23-07:00低用量ケタミンで ICU のオピオイド使用量を軽減　― 機械換気患者を対象とした二重盲検ランダム化試験からの知見 https://news.medxy.ai/vi/low-dose-ketamine-opioid-reduction/Medxy AIvi2026-09-20T08:49:00-07:00Ketamine liều thấp giúp giảm nhu cầu opioid ở bệnh nhân ICU thở máy: Những phát hiện từ một thử nghiệm ngẫu nhiên mù đôi https://news.medxy.ai/low-dose-ketamine-reduces-opioid-requirements-in-mechanically-ventilated-icu-patients-insights-from-a-double-blind-randomized-trial/Medxy AIen2026-09-20T08:48:38-07:00Low-Dose Ketamine Reduces Opioid Requirements in Mechanically Ventilated ICU Patients: Insights from a Double-Blind Randomized Trial https://news.medxy.ai/zh/icu-survivors-driving-2/Medxy AIzh2026-09-20T08:47:56-07:00ICU幸存者如何安全恢复驾驶：一项全面驾驶评估研究的启示 https://news.medxy.ai/ja/icu-survivors-driving/Medxy AIja2026-09-20T08:47:35-07:00ICU生存者の運転再開を可能にするために：包括的運転評価研究から得られた知見 https://news.medxy.ai/vi/driving-ability-survivors/Medxy AIvi2026-09-20T08:47:12-07:00Khả năng quay lại lái xe ở người sống sót sau ICU: phát hiện từ nghiên cứu đánh giá lái xe toàn diện https://news.medxy.ai/enabling-driving-resumption-in-icu-survivors-insights-from-a-comprehensive-driving-assessment-study/Medxy AIen2026-09-20T08:46:49-07:00Enabling Driving Resumption in ICU Survivors: Insights from a Comprehensive Driving Assessment Study https://news.medxy.ai/ja/75767-2/Medxy AIja2026-09-20T08:46:08-07:00救急診療における診断の卓越性と診断見落としの機会：実践と研究に関する重要なコンセンサスと提言 https://news.medxy.ai/vi/diagnostic-consensus/Medxy AIvi2026-09-20T08:45:29-07:00Đồng thuận mới về chẩn đoán xuất sắc và cơ hội chẩn đoán bị bỏ sót tại khoa Cấp cứu: Khuyến nghị cốt lõi cho thực hành và nghiên cứu https://news.medxy.ai/zh/emergency-diagnosis-consensus/Medxy AIzh2026-09-20T08:44:52-07:00急诊诊断卓越与遗漏诊断机会：实践与研究的关键共识建议 https://news.medxy.ai/defining-diagnostic-excellence-and-missed-diagnostic-opportunity-in-the-emergency-department-key-consensus-recommendations-for-practice-and-research/Medxy AIen2026-09-20T08:44:14-07:00Defining Diagnostic Excellence and Missed Diagnostic Opportunity in the Emergency Department: Key Consensus Recommendations for Practice and Research https://news.medxy.ai/dexmedetomidine-continuous-infusion-to-maintain-sedation-in-severely-agitated-adolescents-in-the-emergency-department-a-case-series-report/Medxy AIen2026-09-20T08:43:24-07:00Dexmedetomidine Continuous Infusion to Maintain Sedation in Severely Agitated Adolescents in the Emergency Department: A Case Series Report https://news.medxy.ai/zh/clinical-research-training/Medxy AIzh2026-09-20T08:42:44-07:00真实临床试验中的医学生研究培训新模式：以双导师与实践带教提升胜任力 https://news.medxy.ai/ja/clinical-research-education/Medxy AIja2026-09-20T08:42:24-07:00医学生の臨床研究教育を刷新する：真正なメンタリングと実践で育む能力向上 https://news.medxy.ai/vi/clinical-research-training-2/Medxy AIvi2026-09-20T08:41:58-07:00Đổi mới đào tạo nghiên cứu lâm sàng cho sinh viên y khoa bậc đại học: Nâng cao năng lực thông qua cố vấn chân thực và thực hành https://news.medxy.ai/innovative-clinical-research-training-for-medical-undergraduates-enhancing-competency-through-authentic-mentorship-and-practice/Medxy AIen2026-09-20T08:41:34-07:00Innovative Clinical Research Training for Medical Undergraduates: Enhancing Competency through Authentic Mentorship and Practice https://news.medxy.ai/enhancing-interprofessional-teamwork-in-icu-developing-entrustable-professional-activities-for-trainees-and-advanced-practice-providers/Medxy AIen2026-09-20T08:40:44-07:00Enhancing Interprofessional Teamwork in ICU: Developing Entrustable Professional Activities for Trainees and Advanced Practice Providers https://news.medxy.ai/ja/medical-ethics-ai/Medxy AIja2026-09-20T08:40:04-07:00AI時代の医療倫理と専門職性：American College of Physicians 2026年ポジションペーパーの要点 https://news.medxy.ai/vi/ethics-professionalism-ai/Medxy AIvi2026-09-20T08:39:24-07:00Đạo đức và tính chuyên nghiệp trong AI và thực hành y khoa: Hướng dẫn then chốt từ American College of Physicians (Bản tuyên bố lập trường 2026) https://news.medxy.ai/zh/ai-medical-ethics/Medxy AIzh2026-09-20T08:38:41-07:00AI与医疗实践中的伦理与专业精神：美国内科医师学会2026年立场文件要点 https://news.medxy.ai/ethics-and-professionalism-in-ai-and-medical-practice-key-guidance-from-the-american-college-of-physicians-2026-position-paper/Medxy AIen2026-09-20T08:38:04-07:00Ethics and Professionalism in AI and Medical Practice: Key Guidance from the American College of Physicians (2026 Position Paper) https://news.medxy.ai/ja/2025-va-dod-lipid-guidelines/Medxy AIja2026-09-20T08:37:07-07:002025年VA/DoD脂質管理ガイドライン要点：臨床医が押さえるべきポイント https://news.medxy.ai/vi/va-dod-lipid-guide/Medxy AIvi2026-09-20T08:36:22-07:00Tóm lược hướng dẫn quản lý lipid VA/DoD 2025: điều bác sĩ lâm sàng cần biết https://news.medxy.ai/zh/2025-lipid-guidelines/Medxy AIzh2026-09-20T08:35:38-07:002025年VA/DoD血脂管理指南速览：临床医生必须掌握的要点 https://news.medxy.ai/a-synopsis-of-the-2025-va-dod-lipid-management-guideline-what-clinicians-need-to-know/Medxy AIen2026-09-20T08:35:02-07:00A Synopsis of the 2025 VA/DoD Lipid Management Guideline: What Clinicians Need to Know https://news.medxy.ai/zh/75710-2/Medxy AIzh2026-09-20T08:33:54-07:00AL型淀粉样变性患者接受自体干细胞移植的当代疗效：一项为期十年多中心研究的启示 https://news.medxy.ai/ja/75708-2/Medxy AIja2026-09-20T08:33:30-07:00ALアミロイドーシスにおける自家幹細胞移植の現代的成績：10年にわたる多施設共同研究からの知見 https://news.medxy.ai/vi/75705-2/Medxy AIvi2026-09-20T08:33:06-07:00Kết quả hiện đại của phương pháp ghép tế bào gốc tự thân trong bệnh amyloidosis AL: Những hiểu biết từ nghiên cứu đa trung tâm kéo dài 10 năm https://news.medxy.ai/contemporary-outcomes-of-autologous-stem-cell-transplantation-in-al-amyloidosis-insights-from-a-decade-long-multicenter-study/Medxy AIen2026-09-20T08:32:44-07:00Contemporary Outcomes of Autologous Stem Cell Transplantation in AL Amyloidosis: Insights from a Decade-Long Multicenter Study https://news.medxy.ai/zh/hodgkin-lymphoma-age-treatment/Medxy AIzh2026-09-20T08:32:05-07:00经典型霍奇金淋巴瘤中年龄、蒽环类药物应用与死亡结局：来自大规模完整人群队列的启示 https://news.medxy.ai/vi/75696-2/Medxy AIvi2026-09-20T08:31:17-07:00Tuổi tác và Anthracycline ảnh hưởng đến tỷ lệ tử vong ở bệnh nhân u lympho Hodgkin https://news.medxy.ai/age-anthracycline-use-and-mortality-outcomes-in-classic-hodgkin-lymphoma-insights-from-a-large-complete-population-cohort/Medxy AIen2026-09-20T08:30:52-07:00Age, Anthracycline Use, and Mortality Outcomes in Classic Hodgkin Lymphoma: Insights from a Large Complete Population Cohort https://news.medxy.ai/zh/clag-m-vs-cpx-351-aml/Medxy AIzh2026-09-20T08:30:07-07:00CLAG-M 与 CPX-351 在医学上不适合强化治疗的 AML 成人中的比较：一项评估生存与缓解结局的随机Ⅱ期研究 https://news.medxy.ai/ja/75686-2/Medxy AIja2026-09-20T08:29:43-07:00急性骨髄性白血病（AML）の医学的に不適格な成人患者におけるCPX-351対CLAG-M https://news.medxy.ai/vi/cpx351-clagm-aml/Medxy AIvi2026-09-20T08:29:14-07:00CPX-351 và CLAG-M ở người lớn mắc AML không đủ điều kiện điều trị tích cực: Thử nghiệm ngẫu nhiên pha 2 đánh giá sống còn và đáp ứng https://news.medxy.ai/cpx-351-versus-clag-m-in-medically-unfit-adults-with-aml-a-phase-2-randomized-study-evaluating-survival-and-response-outcomes/Medxy AIen2026-09-20T08:28:47-07:00CPX-351 versus CLAG-M in Medically Unfit Adults with AML: A Phase 2 Randomized Study Evaluating Survival and Response Outcomes https://news.medxy.ai/zh/sickle-cell-blood-brain-barrier/Medxy AIzh2026-09-20T08:27:21-07:00从蛋白质组学看镰状细胞病中血脑屏障破坏的全身驱动因素 https://news.medxy.ai/ja/blood-brain-barrier-failure/Medxy AIja2026-09-20T08:26:47-07:00プロテオミクスで読み解く、鎌状赤血球症における血液脳関門破綻の全身性ドライバー https://news.medxy.ai/vi/blood-brain-barrier-sickle-cell/Medxy AIvi2026-09-20T08:26:22-07:00Giải mã các yếu tố toàn thân gây gián đoạn hàng rào máu – não trong bệnh hồng cầu hình liềm: Góc nhìn từ phân tích proteomic https://news.medxy.ai/unveiling-the-systemic-drivers-of-blood-brain-barrier-disruption-in-sickle-cell-disease-insights-from-proteomic-profiling/Medxy AIen2026-09-20T08:25:59-07:00Unveiling the Systemic Drivers of Blood-Brain Barrier Disruption in Sickle Cell Disease: Insights from Proteomic Profiling https://news.medxy.ai/zh/integrin-%ce%b1iib%ce%b23-deficiency/Medxy AIzh2026-09-20T08:25:16-07:00整合素 αIIbβ3 缺乏如何通过巨核细胞丝氨酸代谢紊乱削弱血小板生成 https://news.medxy.ai/ja/integrin-deficiency-platelet-formation/Medxy AIja2026-09-20T08:24:49-07:00インテグリン αIIbβ3 欠損は巨核球のセリン代謝異常を介して血小板形成を障害する https://news.medxy.ai/vi/75665-2/Medxy AIvi2026-09-20T08:24:20-07:00Sự thiếu hụt integrin αIIbβ3 làm suy giảm quá trình sản sinh tiểu cầu https://news.medxy.ai/integrin-deficiency-platelets/Medxy AIen2026-09-20T08:23:50-07:00Integrin αIIbβ3 Deficiency Impairs Platelet Formation Through Serine Metabolic Dysregulation in Megakaryocytes https://news.medxy.ai/zh/75658-2/Medxy AIzh2026-09-20T08:23:14-07:00医院转入率对风险调整后结局的影响：一项全国性回顾性队列研究的启示 https://news.medxy.ai/ja/75657-2/Medxy AIja2026-09-20T08:22:50-07:00リスク調整後転帰に対する院外からの転院受け入れ頻度の影響：全国規模のレトロスペクティブ・コホート研究からの知見 https://news.medxy.ai/vi/75656-2/Medxy AIvi2026-09-20T08:22:21-07:00Tác động của tỷ lệ bệnh nhân chuyển đến đối với các kết quả lâm sàng đã hiệu chỉnh theo nguy cơ https://news.medxy.ai/impact-of-hospital-transfer-in-prevalence-on-risk-adjusted-outcomes-insights-from-a-national-retrospective-cohort-study/Medxy AIen2026-09-20T08:21:53-07:00Impact of Hospital Transfer-In Prevalence on Risk-Adjusted Outcomes: Insights from a National Retrospective Cohort Study https://news.medxy.ai/zh/brain-natriuretic-peptide/Medxy AIzh2026-09-20T08:21:01-07:00肺动脉内膜剥脱术后脑钠肽水平：慢性血栓栓塞性肺动脉高压患者的预后生物标志物 https://news.medxy.ai/ja/cns-peptide-biomarker/Medxy AIja2026-09-20T08:20:40-07:00慢性血栓塞栓性肺高血圧症における肺動脈内膜剥離術後の予後バイオマーカーとしての脳性ナトリウム利尿ペプチド https://news.medxy.ai/vi/bnp-pulmonary-endarterectomy/Medxy AIvi2026-09-20T08:20:16-07:00BNP sau phẫu thuật pulmonary endarterectomy: Dấu ấn tiên lượng tử vong ở CTEPH https://news.medxy.ai/brain-natriuretic-peptide-levels-as-a-prognostic-biomarker-after-pulmonary-endarterectomy-in-chronic-thromboembolic-pulmonary-hypertension/Medxy AIen2026-09-20T08:19:53-07:00Brain Natriuretic Peptide Levels as a Prognostic Biomarker After Pulmonary Endarterectomy in Chronic Thromboembolic Pulmonary Hypertension https://news.medxy.ai/zh/fibrosis-exercise-comparison/Medxy AIzh2026-09-20T08:19:12-07:00纤维化性间质性肺疾病中高强度间歇训练与中等强度持续训练的比较：随机对照试验的启示 https://news.medxy.ai/ja/75647-2/Medxy AIja2026-09-20T08:18:53-07:00線維化性間質性肺疾患における高強度インターバルトレーニングと中等強度持続トレーニングの比較：ランダム化比較試験からの示唆 https://news.medxy.ai/vi/hiit-vs-mit-fibrosis/Medxy AIvi2026-09-20T08:18:24-07:00Huấn luyện ngắt quãng cường độ cao so với huấn luyện liên tục cường độ vừa trong bệnh phổi kẽ xơ hóa: Góc nhìn từ một thử nghiệm ngẫu nhiên có đối chứng https://news.medxy.ai/evaluating-high-intensity-interval-training-versus-moderate-intensity-continuous-training-in-fibrotic-interstitial-lung-disease-insights-from-a-randomized-controlled-trial/Medxy AIen2026-09-20T08:17:59-07:00Evaluating High Intensity Interval Training Versus Moderate Intensity Continuous Training in Fibrotic Interstitial Lung Disease: Insights from a Randomized Controlled Trial https://news.medxy.ai/zh/glp-1-sleep-apnea/Medxy AIzh2026-09-20T08:17:18-07:00GLP-1受体激动剂能否预防2型糖尿病中的阻塞性睡眠呼吸暂停？英国大型队列研究提示无明显获益 https://news.medxy.ai/ja/75642-2/Medxy AIja2026-09-20T08:16:54-07:00GLP-1受容体作動薬は2型糖尿病患者における閉塞性睡眠時無呼吸を予防できるか？ https://news.medxy.ai/vi/glp-1-receptor-agonists-sleep-apnea-prevention/Medxy AIvi2026-09-20T08:16:27-07:00Chất chủ vận thụ thể GLP-1 và phòng ngừa hội chứng ngưng thở khi ngủ do tắc nghẽn ở đái tháo đường típ 2: Bằng chứng từ một nghiên cứu đoàn hệ lớn tại Vương quốc Anh https://news.medxy.ai/glp-1-receptor-agonists-and-the-prevention-of-obstructive-sleep-apnea-in-type-2-diabetes-insights-from-a-large-uk-cohort-study/Medxy AIen2026-09-20T08:16:02-07:00GLP-1 Receptor Agonists and the Prevention of Obstructive Sleep Apnea in Type 2 Diabetes: Insights from a Large UK Cohort Study